AcquisitionOther
Mirati Therapeutics, Inc. acquired Mirati
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Mirati Therapeutics, Inc. -> Mirati · $58.00
Miratis assets are a strong fit with Bristol Myers Squibbs portfolio and innovative pipeline and represent an attractive opportunity to grow Bristol Myers Squibbs oncology franchise.
Open source record (SEC) ↗